Welcome to our dedicated page for ACADIA PHARMACEUTICALS SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acadia Pharmaceuticals Inc. filings document the regulatory record for a commercial biopharmaceutical company focused on neurological and rare diseases. Recent Form 8-K reports furnish quarterly and annual operating results, product-sales disclosures for NUPLAZID and DAYBUE, corporate presentations and Regulation FD materials, and updates tied to research-and-development leadership.
Proxy and governance filings describe board composition, committee service, director compensation, executive compensation, equity-incentive awards and annual meeting matters. The filings also record board appointments and resignations, non-employee director compensation under equity plans, and other material-event disclosures affecting Acadia’s governance and capital structure.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara exercised and vested equity awards and sold shares to cover taxes. On May 1, 2026, he exercised 2,596 restricted stock units, receiving the same number of common shares at $0.00 per share. On May 4, 2026, 1,332 common shares were sold at a weighted average price of $21.79, with footnotes stating these mandatory sales were solely to cover withholding taxes and tax-related items in connection with the RSU vesting and intended to meet Rule 10b5-1(c) requirements. After these transactions, he directly held 29,129 common shares.
ACADIA PHARMACEUTICALS INC EVP and CFO Mark C. Schneyer reported routine equity compensation activity involving restricted stock units and related tax sales. On May 1, 2026, restricted stock units representing 6,815 shares of common stock vested and were exercised at $0.00 per share.
On May 4, 2026, 3,506 shares of common stock were sold in open-market transactions at a weighted average price of $21.79 per share to cover withholding taxes and tax-related items tied to this vesting, consistent with Rule 10b5-1(c) requirements. After these transactions, Schneyer directly held 66,145 shares of common stock.
Acadia Pharmaceuticals Inc. announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development. Dr. Thompson, who joined the company in 2024, is retiring for personal reasons and will remain in her role during a transitional period until a successor is appointed.
After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to support continuity, including through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis and into early Phase 3 execution. Ongoing clinical trials, including Phase 2 studies of remlifanserin in Alzheimer’s disease psychosis and Lewy Body Dementia Psychosis, are continuing as planned, and the company has begun a search for a new Head of Research and Development.
Vanguard Portfolio Management reports beneficial ownership of 8,781,007 shares of ACADIA Pharmaceuticals Inc Common Stock. The filing states this equals 5.15% of the class, with 109,362 shares subject to sole voting power and 8,781,007 shares subject to sole dispositive power as of 03/31/2026. The disclosure describes holdings managed across Vanguard Portfolio Management LLC and affiliated business divisions.
Acadia Pharmaceuticals is holding its 2026 annual stockholder meeting virtually on May 29, 2026 at 8:00 a.m. Pacific time. Stockholders of record as of April 14, 2026 may vote online on several key items.
Proposals include electing three Class I directors to serve until the 2029 meeting, an advisory “say-on-pay” vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to increase the shares authorized for issuance by 5,209,670, adjust the counting ratio for full-value awards, and raise the maximum shares available for incentive stock options. The Board recommends voting “FOR” all four proposals.
ACADIA Pharmaceuticals EVP and CFO Mark C. Schneyer reported routine equity compensation activity involving restricted stock units and related tax sales. On April 5, 5,276 restricted stock units were exercised into 5,276 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings. The restricted stock units vest in four equal annual installments beginning April 5, 2023.
On April 7, 2,709 shares of common stock were sold at $22.20 per share, leaving Schneyer with 62,836 shares directly owned after the transactions. According to the disclosure, these mandatory sales were made to cover withholding taxes and related items in connection with the RSU vesting and are intended to comply with Rule 10b5-1(c) under the Exchange Act.
ACADIA PHARMACEUTICALS’ principal accounting officer, James Kihara, reported routine RSU vesting and related tax sales. On April 5, 2026, 2,010 restricted stock units were converted into 2,010 shares of common stock at $0.00 per share. The same RSU grant vests in four equal annual installments beginning April 5, 2023.
On April 7, 2026, 1,030 of these shares were sold in open-market transactions at a weighted-average price of $22.20 per share, with actual prices ranging from $22.07 to $22.20. A footnote states these mandatory sales were made to cover withholding taxes and related tax items in connection with the RSU vesting and are intended to comply with Rule 10b5-1(c). After these transactions, Kihara directly holds 27,865 shares of Acadia common stock.
ACADIA PHARMACEUTICALS Chief Executive Officer Catherine Owen Adams reported routine equity transactions linked to restricted stock unit vesting. On March 24, 2026, she exercised 23,509 restricted stock units, receiving the same number of common shares at a $0.00 conversion price and increasing her direct common stock holdings to 26,444 shares.
On March 25, 2026, she made an open-market sale of 11,641 common shares at $21.47 per share. Footnotes state these mandatory sales were to cover withholding taxes and related items in connection with restricted stock unit vesting and are intended to comply with Rule 10b5-1(c). Following the sale, she directly holds 14,803 common shares and 70,530 restricted stock units, which vest in four equal annual installments beginning March 24, 2026.
ACADIA Pharmaceuticals EVP Elizabeth H.Z. Thompson reported routine equity compensation activity. On March 24, 2026, she acquired 6,715 shares of common stock at $0.00 per share upon vesting of restricted stock units, increasing her direct holdings to 6,715 shares and 20,146 restricted stock units. On March 25, 2026, 3,435 shares were sold at $21.47 per share to cover withholding taxes and related items under a Rule 10b5-1 arrangement, leaving her with 3,280 common shares directly. The restricted stock units vest in four equal annual installments beginning March 24, 2026.